Whereas phase III trials with the anti-MUC1 vaccines Tecemotide in patients with stage III non-small-cell lung cancer and PANVAC C/F in patients with stage IV pancreatic cancer did not show survival benefits compared to standard therapy [19, 20], various studies are investigating anti-MUC1 peptide, carbohydrate, DNA, and dendritic cells (DC) vaccines [35]. Here, MUC1 is linked to non-small cell lung carcinoma.